IL6R and Sepsis: Our findings demonstrate that YTHDF2 plays an essential role as an inhibitor of inflammation by reducing the release of HMGB1 via inhibition of IL-6R/JAK2/STAT1 signalling, indicating that this pathway may be a novel therapeutic strategy for sepsis.